These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 20064438)
21. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Loidl G; Groll M; Musiol HJ; Ditzel L; Huber R; Moroder L Chem Biol; 1999 Apr; 6(4):197-204. PubMed ID: 10099130 [TBL] [Abstract][Full Text] [Related]
22. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells. Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199 [TBL] [Abstract][Full Text] [Related]
23. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Ma W; Kantarjian H; Bekele B; Donahue AC; Zhang X; Zhang ZJ; O'Brien S; Estey E; Estrov Z; Cortes J; Keating M; Giles F; Albitar M Clin Cancer Res; 2009 Jun; 15(11):3820-6. PubMed ID: 19458051 [TBL] [Abstract][Full Text] [Related]
24. [Dynamic Changes in the Activities and Contents of Particular Proteasome Forms in the Cerebral Cortex of C57BL/6 Mice during Aging]. Burov AV; Funikov SY; Astakhova TM; Teterina EV; Nebogatikov VO; Erokhov PA; Ustyugov AA; Karpov VL; Morozov AV Mol Biol (Mosk); 2023; 57(5):886-894. PubMed ID: 37752653 [TBL] [Abstract][Full Text] [Related]
25. Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers. Loy CA; Muli CS; Ali EMH; Xie D; Ahmed MH; Beth Post C; Trader DJ Bioorg Med Chem Lett; 2023 Oct; 95():129485. PubMed ID: 37714498 [TBL] [Abstract][Full Text] [Related]
26. New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity. Neilsen PM; Pehere AD; Pishas KI; Callen DF; Abell AD ACS Chem Biol; 2013 Feb; 8(2):353-9. PubMed ID: 23190346 [TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Genin E; Reboud-Ravaux M; Vidal J Curr Top Med Chem; 2010; 10(3):232-56. PubMed ID: 20166955 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous fluorescent monitoring of proteasomal subunit catalysis. Wakata A; Lee HM; Rommel P; Toutchkine A; Schmidt M; Lawrence DS J Am Chem Soc; 2010 Feb; 132(5):1578-82. PubMed ID: 20078037 [TBL] [Abstract][Full Text] [Related]
29. Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells. Ding Y; Chen X; Wang B; Yu B; Ge J; Shi X Can J Physiol Pharmacol; 2018 May; 96(5):521-526. PubMed ID: 29394494 [TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Roccaro AM; Sacco A; Aujay M; Ngo HT; Azab AK; Azab F; Quang P; Maiso P; Runnels J; Anderson KC; Demo S; Ghobrial IM Blood; 2010 May; 115(20):4051-60. PubMed ID: 20110419 [TBL] [Abstract][Full Text] [Related]
31. Activation and inhibition of the proteasome by betulinic acid and its derivatives. Huang L; Ho P; Chen CH FEBS Lett; 2007 Oct; 581(25):4955-9. PubMed ID: 17904555 [TBL] [Abstract][Full Text] [Related]
32. The proteasome: structure, function, and role in the cell. Adams J Cancer Treat Rev; 2003 May; 29 Suppl 1():3-9. PubMed ID: 12738238 [TBL] [Abstract][Full Text] [Related]
33. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome. Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024 [TBL] [Abstract][Full Text] [Related]
34. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Elofsson M; Splittgerber U; Myung J; Mohan R; Crews CM Chem Biol; 1999 Nov; 6(11):811-22. PubMed ID: 10574782 [TBL] [Abstract][Full Text] [Related]
35. Regulation of the ubiquitin proteasome system in mechanically injured human skeletal muscle. Seiffert M; Gosenca D; Ponelies N; Ising N; Patel MB; Obertacke U; Majetschak M Physiol Res; 2007; 56(2):227-233. PubMed ID: 16555940 [TBL] [Abstract][Full Text] [Related]
36. Identification of Novel Proteasome Inhibitors from an Enaminone Library. Elliott ML; Thomas K; Kennedy S; Koduri ND; Hussaini RS; Sheaff RJ Chem Biol Drug Des; 2015 Sep; 86(3):322-32. PubMed ID: 25494709 [TBL] [Abstract][Full Text] [Related]
37. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511 [TBL] [Abstract][Full Text] [Related]
38. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. Hunter JM; Lesort M; Johnson GV J Neurosci Res; 2007 Jun; 85(8):1774-88. PubMed ID: 17455294 [TBL] [Abstract][Full Text] [Related]
39. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872 [TBL] [Abstract][Full Text] [Related]
40. Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity. Wilkins OM; Downey SL; Weyburne ES; Williams DA; Mirabella AC; Overkleeft HS; Kisselev AF Anal Biochem; 2014 Apr; 451():1-3. PubMed ID: 24486333 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]